US Patent 11534453 RNAi therapy for hepatitis B virus infection
Patent 11534453 was granted and assigned to Arrowhead Pharmaceuticals, Inc. on December, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 28 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 25 Apr, 2023
Golden AI
Infobox
Edits on 23 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 7 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 29 Mar, 2023
Golden AI
Infobox
Patent Citations
Edits on 28 Mar, 2023
Golden AI
Edits on 26 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115344530
Date of Patent
December 27, 2022
0Patent Application Number
170160210
Date Filed
September 9, 2020
0Patent Citations
Patent Primary Examiner
Golden AI
Infobox
Patent Citations
Edits on 28 Dec, 2022
Golden AI
Edits made to:
Infobox (+25 properties)
Article (+496 characters)
US Patent 11534453 RNAi therapy for hepatitis B virus infection
Article
Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hepatitis B virus gene are described. Pharmaceutical compositions comprising one or more HBV RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi triggers to infected liver in vivo provides for inhibition of HBV gene expression and treatment.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
115344530
Date of Patent
December 27, 2022
0Patent Application Number
170160210
Date Filed
September 9, 2020
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11534453 RNAi therapy for hepatitis B virus infection
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
